Published in Cell Signal on May 01, 2002
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat (2007) 3.78
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
An activating mutation of AKT2 and human hypoglycemia. Science (2011) 2.60
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol (2007) 2.28
Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology (2013) 2.21
Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol (2003) 2.20
High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One (2012) 2.17
Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol (2009) 2.15
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
The molecular pathogenesis of osteosarcoma: a review. Sarcoma (2011) 1.91
Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J (2005) 1.85
Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet (2004) 1.85
Main roads to melanoma. J Transl Med (2009) 1.67
NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell (2013) 1.67
Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol Cell Biol (2003) 1.67
The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res (2009) 1.62
Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61
EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem (2007) 1.59
Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol (2007) 1.54
Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol (2003) 1.53
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52
A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res (2009) 1.48
Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients. Br J Cancer (2006) 1.47
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther (2005) 1.46
MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. PLoS One (2015) 1.43
PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt. Proc Natl Acad Sci U S A (2004) 1.43
Raw single-wall carbon nanotubes induce oxidative stress and activate MAPKs, AP-1, NF-kappaB, and Akt in normal and malignant human mesothelial cells. Environ Health Perspect (2008) 1.40
Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther (2010) 1.39
Osmoprotective transcription factor NFAT5/TonEBP modulates nuclear factor-kappaB activity. Mol Biol Cell (2010) 1.38
Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res (2006) 1.36
Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol Cancer (2009) 1.35
Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer (2003) 1.34
Proteomic changes resulting from gene copy number variations in cancer cells. PLoS Genet (2010) 1.32
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res (2009) 1.31
ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol (2004) 1.29
Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem (2009) 1.28
Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res (2008) 1.26
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2006) 1.25
Regulation of the activity of p38 mitogen-activated protein kinase by Akt in cancer and adenoviral protein E1A-mediated sensitization to apoptosis. Mol Cell Biol (2003) 1.23
Protein kinases and phosphatases in the control of cell fate. Enzyme Res (2011) 1.23
The eIF4E RNA regulon promotes the Akt signaling pathway. J Cell Biol (2008) 1.22
Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci (2012) 1.22
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 1.22
Targeting Akt3 signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res (2009) 1.22
CARMA1 is required for Akt-mediated NF-kappaB activation in T cells. Mol Cell Biol (2006) 1.21
Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death. Biophys J (2006) 1.20
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2011) 1.19
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res (2008) 1.15
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke. Front Mol Neurosci (2011) 1.14
Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res (2006) 1.14
Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol (2010) 1.14
Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia (2012) 1.14
Role of Bax in quercetin-induced apoptosis in human prostate cancer cells. Biochem Pharmacol (2008) 1.13
Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10
Akt2: a role in breast cancer metastasis. Breast Cancer Res (2003) 1.10
Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther (2008) 1.09
Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther (2010) 1.08
In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res (2009) 1.08
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin Cancer Res (2010) 1.07
Greglist: a database listing potential G-quadruplex regulated genes. Nucleic Acids Res (2007) 1.07
PI-3K/Akt pathway-dependent cyclin D1 expression is responsible for arsenite-induced human keratinocyte transformation. Environ Health Perspect (2008) 1.06
Fish oil targets PTEN to regulate NFkappaB for downregulation of anti-apoptotic genes in breast tumor growth. Breast Cancer Res Treat (2008) 1.06
Solution structure and backbone dynamics of the pleckstrin homology domain of the human protein kinase B (PKB/Akt). Interaction with inositol phosphates. J Biomol NMR (2004) 1.06
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clin Cancer Res (2009) 1.06
M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol (2006) 1.05
High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med (2008) 1.05
Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy. Autophagy (2012) 1.05
Ablation of Akt2 induces autophagy through cell cycle arrest, the downregulation of p70S6K, and the deregulation of mitochondria in MDA-MB231 cells. PLoS One (2011) 1.04
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol (2011) 1.04
Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer (2006) 1.04
Zerumbone suppresses IKKα, Akt, and FOXO1 activation, resulting in apoptosis of GBM 8401 cells. J Biomed Sci (2012) 1.04
Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res (2009) 1.03
The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling. Cancer Chemother Pharmacol (2006) 1.03
Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells. Front Oncol (2013) 1.02
Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol (2009) 1.02
Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis (2008) 1.02
Oscillations of the p53-Akt network: implications on cell survival and death. PLoS One (2009) 1.02
The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res (2010) 1.02
Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br J Cancer (2010) 1.02
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer (2010) 1.02
Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells. Infect Immun (2008) 1.02
The Paradox of Akt-mTOR Interactions. Front Oncol (2013) 1.02
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway. Br J Cancer (2014) 1.01
A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One (2011) 1.01
PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer (2013) 1.01
Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis (2010) 1.00
Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells. J Am Coll Surg (2009) 1.00
Novel Insights into the Interplay between Apoptosis and Autophagy. Int J Cell Biol (2012) 1.00
Autophagy inhibitor chloroquine enhanced the cell death inducing effect of the flavonoid luteolin in metastatic squamous cell carcinoma cells. PLoS One (2012) 0.99
The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adh Migr (2012) 0.99
Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res (2009) 0.99
Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation. Lab Invest (2009) 0.99
Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst (2007) 2.75
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem (2003) 1.18
"Flow valve" microfluidic devices for simple, detectorless, and label-free analyte quantitation. Anal Chem (2012) 0.76